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Hepatic Arterial Infusion Therapy with Cisplatin using Protein Binding Inhibition:
Pharmacokinetics and Antineoplastic Effects of Cisplatin Combined with L-Cysteine in Rats
　Covalent binding is involved in the protein binding of cisplatin. L-cysteine reduces the covalent 
binding of cisplatin. We investigated hepatic arterial infusion therapy with cisplatin using protein 
binding inhibition. In the present experiment, the pharmacokinetics and antineoplastic effects of 
cisplatin combined with L-cysteine in male Donryu rats were investigated. As a result, no significant 
difference was noted in the total and free concentrations of cisplatin combined with L-cysteine. In 
an in vivo experiment using rats with liver cancer, the hepatic arterial infusion of cisplatin combined 
with L-cysteine showed that it was the tendency that tumor growth rate was inhibited in comparison 
with administration only for cisplatin. In addition, concentrations of cisplatin increased significantly 
between tumor and non-tumor regions in liver tissue when combined with L-cysteine (p<0.01). Thus, 
L-cysteine can be combined with cisplatin for hepatic arterial infusion therapy.
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INTRODUCTION
　The effects of drug therapy generally depend on 
the concentration of free drug that is not bound 
to human serum proteins and thus remains free to 
exert its therapeutic effect. The protein binding rate 
of cisplatin (cis-diamminedichloroplatinum [II]) in 
the blood is about 90%1). Cisplatin plays a major 
role in cancer chemotherapy. Cisplatin may not 
exert sufficient effects after administration because 
of a low free drug concentration. Cisplatin is locally 
administered around the tumor by hepatic arterial 
infusion as well as systemic administration. In 
transcatheter hepatic arterial chemoembolization 
(TACE), cisplatin should accumulate around 
the tumor, when combined with an embolus 
material, to disrupt the nutrient supply to the 
tumor. Inhibiting the protein binding of cisplatin 
may increase the free cisplatin concentration to 
facilitate cisplatin migration to tumor tissue. We 
have demonstrated that cisplatin binds mainly to 
human serum albumin (HSA) among human plasma 
proteins, and reported the involvement of covalent 
binding because of a time-dependent increase in 
the protein binding rate of cisplatin. The covalent 
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binding site with HSA is a free SH group in Cys342). 
We considered it beneficial to make this free SH 
group bind to a certain safe substance beforehand. 
Then, we demonstrated that L-cysteine with a SH 
group reduces the covalent binding of cisplatin3). 
Thus, we examined the application of hepatic 
arterial infusion therapy with cisplatin using protein 
binding inhibition. In the present study, we report 
the effects of the concomitant use of L-cysteine 
on the pharmacokinetics and protein binding of 
cisplatin in rats and the antineoplastic effects of 




　Male Donryu rats (Charles River Japan) were 
used. The rats were allowed free access to food and 
water for 1-week preliminary rearing.
Reagents
　Cisplatin powder was supplied by Nippon Kayaku 
Co., Ltd. L-cysteine were purchased from Wako 
Pure Chemical Industries, Ltd. All other reagents 
used were special grade. 
Pharmacokinetics Experiment
　A test protocol on pharmacokinetics is shown 
in Figure 1. The rats were anesthetized with 
pentobarbital (50 mg/kg). A polyethylene tube PE50 
(Becton Dickinson, 0.58-mm internal diameter, 
0.965-mm external diameter) was inserted into 
the carotid artery and jugular vein. The rats were 
divided into three groups. The control group 
received the intravenous (i.v.) administration of 
saline (2 mL/kg), and, subsequently, cisplatin (2 
mg/2 mL/kg) through a jugular cannula. The IV 
group received L-cysteine i.v. (100 mg/2 mL/kg) 
through a jugular cannula, and, subsequently, 
cisplatin i.v. (2 mg/2 mL/kg). The intravenous drip 
injection (DIV) group received L-cysteine d.i.v. 
(100 mg /2 mL/kg) through a jugular cannula for 1 
hour before and after cisplatin administration. To 
prevent blood coagulation, the cannula was flushed 
with 0.1 mL of heparin (100 unit/mL). At 2, 10, 60, 
and 180 min after cisplatin administration, 750μL of 
blood was collected from the jugular cannula. The 
blood was left at room temperature for 30 min and 
centrifuged at 3,000 rpm for 15 min to fractionate 
serum.
Figure. 1  Test Protocol on Pharmacokinetics.
　The rats were divided into three groups. Control 
group: saline + cisplatin i.v., IV group: L-cysteine + 
cisplatin i.v., DIV group: L-cysteine d.i.v. + cisplatin 
i.v..
Measurement of Serum Cisplatin Concentration
　The total serum cisplatin (bound and free 
cisplatin) concentration was determined as 
described below. To determine the serum total 
cisplatin concentration, the collected serum (8μL) 
was 5-fold diluted with blank serum (32μL), and 
the diluted serum was 5-fold diluted with 0.05% 
Triton-X/0.4N HCl (160μL). The 25-fold diluted 
serum thus obtained was used as a measurement 
sample. This sample was used for measurement 
with an atomic absorption photometer (Z-5010, 
Hitachi). Cisplatin reference solutions (0-0.2μg/
mL) were prepared to create a calibration curve. 
The free cisplatin concentration in serum was 
determined as described below. The serum (250μL) 
was centrifuged at 3,200 rpm for 15 min with an 
ultrafilters (MINICENT-10, Tosoh). The obtained 
filtrate (20μL) was 5-fold diluted with purified 
water (80μL) to prepare a measurement sample. 
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This sample was used for measurement with an 
atomic absorption photometer. Cisplatin reference 
solutions (0-1.0μg/mL) were prepared to create a 
calibration curve.
Preparation of Liver Cancer Rat Model
　A rat ascites hepatoma strain, AH-109A, was 
kindly provided by Dr. Kishimoto Shuichi of 
the Faculty of Pharmaceutical Sciences, Kobe 
Gakuin University. The AH-109A cells were 
intraperitoneally subcultured in the ascites of a 
4-week-old rat. A suspension of the subcultured 
AH-109A cells was subcutaneously transplanted 
into another 4-week-old rat. The solid tumor which 
grew up after subcutaneously transplantation was 
removed. The necrotic region was removed from 
the tumor. The tumor was cut into 1-mm pieces 
in a Hanks' balanced salt solution to be used for 
transplantation. A 9-week-old rat weighing about 
400 g underwent laparotomy under Nembutal 
anesthesia. A graft was transplanted into the 
parenchyma of the left lobe of the liver using a 
commercial indwelling venous catheter with a 
20G needle. Specifically, an intravascular emboli-
promoting agent, Gelpart® (Nippon Kayaku), and a 
graft were used to fill the catheter tip in this order. 
The catheter was inserted into the parenchyma of 
the liver using a polyethylene tube PE10 (Becton 
Dickinson, 0.28-mm internal diameter, 0.61-mm 
external diameter) from the connection of the 
catheter syringe. Then, the catheter was removed. 
Figure 2 shows tumor transplantation and hepatic 
arterial infusion sites in a rat model of liver cancer.
Hepatic Arterial Infusion Therapy
　On day 20 after transplantation, the rat 
underwent laparotomy under anesthesia. The 
major and minor axes of the tumor were measured. 
Then, the common hepatic, gastroduodenal, and 
proper hepatic arteries were identified with sutures. 
Subsequently, a polyethylene tube was inserted 
from the gastroduodenal artery to the bifurcation 
of the common hepatic and proper hepatic 
arteries and fixed with a suture. Then, an agent 
was slowly infused into the bloodstream from the 
common hepatic to proper hepatic arteries. After 
the completion of administration, the polyethylene 
tube was removed. The gastroduodenal artery was 
ligated, and the abdomen was sutured. Then, the 
rat was reared under normal conditions.
Figure. 2  Tumor Transplantation and Hepatic 
Arterial Infusion Sites in Rat Model of Liver Cancer.
　A polyethylene tube was inserted from the 
gastroduodenal artery to the bifurcation of the 
common hepatic and proper hepatic arteries and 
fixed with a suture. Then, an agent was slowly 
infused into the bloodstream from the common 
hepatic to proper hepatic arteries.
Antineoplastic Effects
　The rats were divided into three groups. The 
control group received a hepatic arterial infusion 
of saline (2 mL/kg). The cisplatin group received a 
hepatic arterial infusion of cisplatin (2 mg/2 mL/kg). 
The L-cysteine + cisplatin group received L-cysteine 
d.i.v. (100 mg /2 mL/kg) through a jugular cannula 
for 1 hour before and after cisplatin administration. 
Cisplatin was administered by hepatic arterial 
infusion. To prevent blood coagulation, the 
cannula was flushed with 0.1 mL of heparin. On 
day 7 after administration (i.e., on day 27 after 
transplantation), the rat was anatomized to remove 
the liver. The major and minor axes of the tumor 
were measured. Blood was collected from a lower 
leg artery. 
　Tumor growth rate (%) = (major axis x minor 
axis after administration / major axis x minor axis 
before administration) x 100
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Measurement of Cisplatin Concentration in Liver 
Tissue
　The removed liver was divided into tumor and 
non-tumor regions to determine the cisplatin 
concentration in liver tissue. The measurement was 
conducted by NAC Co., Ltd (Tokyo, Japan).
Statistical Analysis
　All results were expressed as the mean ± S.E.. 
The unpaired Student t-test, Bonferroni test, and 
SNK test were employed for two-group, control, 
and multiple- group comparisons, respectively.
RESULTS
Effects of L-Cysteine on Pharmacokinetics of 
Cisplatin
　No significant difference was noted in the total 
and free concentrations among the three groups 
(Figures 3(A) and 3(B)). No effect of L-cysteine was 
noted even in the free fraction (Figure 3(C)). 
Effects of L-Cysteine on Antineoplastic Effects of 
Cisplatin
　The cisplatin group and L-cysteine + cisplatin 
group showed significantly stronger inhibition 
of tumor growth rate compared with the control 
group (p<0.01) together. No significant difference 
was noted between the L-cysteine + cisplatin 
group and cisplatin group, although a tendency to 
inhibit of tumor growth rate was present (Figure 
4). A comparison of the cisplatin concentrations 
in the tumor and non-tumor regions of liver 
tissue between the L-cysteine + cisplatin and 
cisplatin groups demonstrated no difference 
in the concentrations in the non-tumor region 
between the groups, but a higher concentration 
in the tumor region for the L-cysteine + cisplatin 
group (Table 1). The concentrations of cisplatin 
increased significantly between tumor and non-
tumor regions in liver tissue when combined with 
L-cysteine (p<0.01). The cisplatin group showed 
significant weight loss compared with the control 
group (p<0.05). However, no significant difference 
was noted between the L-cysteine + cisplatin and 
control groups (Table 2). All the groups showed 
elevated AST values. However, L-cysteine caused 
no change in AST values. No change was observed 
for the other laboratory values.
Figure. 3  Effects of L-Cysteine on Pharmacokinetics 
of Cisplatin.
(A) Effects of L-Cysteine on Pharmacokinetics of 
Total Cisplatin.
(B) Effects of L-Cysteine on Pharmacokinetics of 
Free Cisplatin.
(C) Effects of L-Cysteine on Pharmacokinetics of 
Free Fraction Cisplatin.
　There is no significant difference. Each value 
represents the mean ± S.E. of seven or eight rats.
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Figure. 4  Effects of L-Cysteine on Antineoplastic 
Effects of Cisplatin.
　The cisplatin group and L-cysteine + cisplatin 
group showed significantly stronger inhibition of 
tumor growth rate compared with the control group 
(p<0.01) together. No significant difference was 
noted between the L-cysteine + cisplatin group 
and cisplatin group, although a tendency to inhibit 
of tumor growth rate was present. Each value 
represents the mean ± S.E. of eight or nine rats.
DISCUSSION
　In an in vivo experiment using rats with liver 
cancer, the hepatic arterial infusion of cisplatin 
combined with L-cysteine showed that it was the 
tendency that tumor growth rate was inhibited in 
comparison with administration only for cisplatin. 
The cisplatin concentrations were significantly 
different between tumor and non-tumor regions 
in liver tissue when cisplatin was combined with 
L-cysteine (p<0.01). 
　To examine the effects of L-cysteine on the 
pharmacokinetics of cisplatin under normal 
conditions, the pharmacokinetics after hepatic 
arterial infusion therapy should be examined on 
day 20 after transplantation. In the present study, 
another experiment was conducted because the 
effects of pharmacokinetic changes, caused by 
blood collection on day 20 after transplantation, 
on the antineoplastic effects on day 7 after hepatic 
arterial infusion (on day 27 after transplantation) 
were undeniable. Thus, in the present study, the 
dosage of L-cysteine (100 mg/2 mL/kg) was 200-
fold higher than that required to achieve a routine 
blood level to examine pharmacokinetic changes. 
However, this dosage is safe in view of the results 
of a single-dose toxicity study (L-cysteine LD50: 
6,350 mg/kg p.o.) 4). The results demonstrated 
no significant difference in the total and free 
concentrations among the three groups. In 
addition, no effect was noted on the free fraction. 
The following reasons were considered: 1) the 
inhibitory effects of L-cysteine were not reflected on 
the blood concentration because of a low binding 
rate at the beginning of cisplatin administration 
(the protein binding rate immediately after the 
addition of cisplatin in human serum was about 
18%3)); 2) cisplatin was systemically administered 
through an intravenous route; and 3) the timing 
of the intravenous drip injection of L-cysteine was 
inappropriate in the DIV group. The dosage and 
administration timing should be examined in detail.
　In the experiment on the antineoplastic effects 
of cisplatin when combined with L-cysteine, 
the protein binding inhibition of L-cysteine may 
have increased the free cisplatin concentration 
in the tumor and enhanced inhibitory effects on 
tumor growth. L-cysteine increases the blood 5-FU 
concentration and enhances antineoplastic effects5, 6). 
Iigo and Kawabata et al. reported that when 5-FU is 
orally administered with L-cysteine, it inhibits drug-
metabolizing enzymes to delay 5-FU metabolism 
and blood concentration reduction, thereby 
enhancing the antineoplastic effects. L-cysteine 
is converted to disulfide cystine or glutathione, 
an important biological sulfhydryl compound, 
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in the living body. Glutathione is medicine for 
chronic liver diseases. Hepatic glutathione is 
depleted during liver injury. L-cysteine prevents 
the glutathione depletion to protect the liver7). 
The L-cysteine + cisplatin group showed a more 
marked inhibition of tumor growth rate than the 
cisplatin group. For this reason, it may be the 
interaction that added the unknown mechanism 
that is different from the protein binding inhibition 
of cisplatin, which we think about it. All the groups 
showed elevated AST values, which may have 
resulted from elevated values in liver cancer. 
　Thus, the concomitant use of L-cysteine may 
be applicable for TACE. For the application, the 
following dosing regimens may be possible. First, 
L-cysteine solution is used in hydration conducted 
before and after cisplatin administration to a 
patient with liver cancer. Routinely, 1,000-2,000 
mL hydration is conducted to alleviate serious side 
effects (e.g., renal damage). The administration 
of an amino acid agent containing L-cysteine 
should inhibit the protein binding of cisplatin to 
increase the free cisplatin concentration, thereby 
enhancing the antineoplastic effects. Second, the 
hepatic arterial infusion of high concentrations of 
L-cysteine through a catheter is employed before 
the local hepatic arterial infusion of cisplatin. Third, 
L-cysteine is orally administered before TACE to 
maintain a high blood L-cysteine concentration, 
thereby inhibiting the protein binding of cisplatin. 
Thus, these dosing regimens of anticancer agents 
using protein binding inhibition should be effective 
even at low doses. To establish these regimens, 
further basic research is needed.
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蛋白結合阻害を利用した cisplatin 肝動注療法に関する研究：
ラットにおける L-cysteine 併用時における cisplatin の体内動態と抗腫瘍効果
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　Cisplatin の蛋白結合には共有結合が関与しており、L-cysteine は cisplatin の共有結合を低下させる。そこ
で、この蛋白結合阻害を利用して cisplatin の肝動注療法の応用性について検討を行った。実験では、Donryu
系雄性ラットにおける L-cysteine 併用時における cisplatin の体内動態と抗腫瘍効果の影響について検討した。
その結果、L-cysteine 併用において cisplatin の total と free 濃度に有意な差はみられなかった。また肝癌ラッ
トを使用した in vivo 実験系において、L-cysteine を併用した cisplatin の肝動注は cisplatin のみの投与に比
べ、腫瘍増殖率が抑えられる傾向であることを示した。さらに肝組織中における腫瘍部と非腫瘍部における
cisplatin 濃度において、L-cysteine 併用により腫瘍部と非腫瘍部に有意な差を認めることができた (p<0.01)。
以上の結果より、L-cysteine の併用は cisplatin の肝動注療法へ応用できると考えられる。
キーワード：シスプラチン、蛋白結合阻害、共有結合、肝動注、L- システイン
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